Over-expression of NFYB affects stromal cells reprogramming and predicts worse survival in gastric cancer patients

Aging (Albany NY). 2022 Sep 22;14(19):7851-7865. doi: 10.18632/aging.204294. Epub 2022 Sep 22.

Abstract

Gastric cancer (GC) is the fifth most common cancer worldwide and the third most fatal. Cancer-associated fibroblasts (CAFs) play an essential role in promoting the occurrence and development of gastric cancer in all stages. NFYB is highly expressed in multiple tumors and promotes tumor invasion, metastasis, and drug resistance, but its role in the occurrence and development of gastric cancer remains unclear. Hence, we used TCGA, TIMER, Kaplan-Meier Plot, and UALCAN databases to analyze the expression of NFYB in pan-cancers and assess its clinical prognostic value. We found that high expression of NFYB may be a promising prognostic biomarker in patients with gastric cancer. High expression of NFYB was associated with high T stage, high histological grade, diffuse gastric cancer, and early-onset GC. Moreover, High expression of NFYB was associated with CAFs infiltration in the GC microenvironment. The prognosis of GC patients with high expression of NFYB and high infiltration of CAFs was worse. Therefore, NFYB may serve as a potential prognostic biomarker in patients with GC.

Keywords: NFYB; cancer-associated fibroblasts (CAFs); gastric cancer; prognosis; stromal cells reprogramming.

MeSH terms

  • Biomarkers / metabolism
  • CCAAT-Binding Factor / metabolism
  • Cancer-Associated Fibroblasts* / metabolism
  • Humans
  • Stomach Neoplasms* / metabolism
  • Stromal Cells / metabolism
  • Tumor Microenvironment / genetics

Substances

  • Biomarkers
  • NFYB protein, human
  • CCAAT-Binding Factor